Skip to content

O'Byrne PM, et al. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med. 2018. PMID 29768149

One-paragraph summary

SYGMA 1 randomized 3,849 people aged at least 12 with mild asthma to as-needed terbutaline, as-needed budesonide–formoterol or maintenance budesonide plus terbutaline for 52 weeks. As-needed budesonide–formoterol produced more well-controlled weeks than terbutaline (34.4% versus 31.1%) but fewer than maintenance budesonide (44.4%). Severe-exacerbation rates were 0.20, 0.07 and 0.09 per year, respectively. Versus terbutaline, the anti-inflammatory reliever rate ratio was 0.36 (95% CI 0.27–0.49), with median ICS exposure 57 μg/day versus 340 μg/day under maintenance budesonide.

Key findings

  • Symptom-control and attack-prevention rankings differed.
  • As-needed budesonide–formoterol sharply reduced severe attacks versus bronchodilator-only relief.
  • Maintenance budesonide delivered better average day-to-day control at much higher ICS exposure.

Limitations

  • Double-dummy trial adherence and monitoring exceed routine practice.
  • The studied dry-powder formulation, dose and minimum age are not interchangeable with every ICS/LABA.
  • Severe attacks were uncommon, so absolute benefit varies with baseline risk.

Why it matters

SYGMA 1 supplied the pivotal mechanistic and clinical logic for an anti-inflammatory reliever: symptoms trigger rapid bronchodilation and an ICS dose together. It also shows why “best regimen” depends on whether the priority is daily control, attack prevention or steroid exposure.

Cited by wiki pages

  • overview
  • mild and moderate asthma
  • clinical trials landscape